ppar

New targets for NAFLD

Authors: Parlati L, Régnier M, Guillou H, et al.
Published in JHEP Rep 2021
NAFLD is a growing cause of chronic liver disease worldwide. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD...
Read More

PPARs as candidates for the treatment of NAFLD

Authors: Fougerat A, Montagner A, Loiseau N, et al
Published in Cells 202
The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD...
Read More

Fibrosis in NASH: targeted therapies

Authors: Huisman TM, Dieterich DT, Friedman SL
Published in J Exp Pharmacol 2021
Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...
Read More

Management of NAFLD: a review

Authors: Petroni ML, Brodosi L, Bugianesi E, et al.
Published in BMJ 2021
As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH. Anti-inflammatory, anti-fibrotic agents and metabolism modulators...
Read More

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

Authors: Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al.
Published in J Hepatol 2020
Advanced chronic liver disease (ACLD) is a serious public health issue for which a safe and effective treatment is still lacking. It is often associated with portal hypertension and liver fibrosis. Over the recent years, peroxisome proliferator-activated receptors family (PPARs) have been considered as a relevant...
Read More

Experimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.

Authors: Lefere S, Puengel T, Hundertmark J, et al.
Published in J Hepatol 2020
In a CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis, S. Lefere et al. studied the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. To examine the pathophysiological sequence of steatohepatitis...
Read More

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

Authors: Lefere S, Puengel T, Hundertmark J, et al.
Published in J Hepatol 2020
In an experimental study, S. Lefere et al. investigated the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. The authors employed the CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis...
Read More

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

Authors: Boeckmans J, Natale A, Rombaut M, et al.
Published in Cell Biol Toxicol 2020
In this study, J. Boeckmans et al. (Faculty of Medicine and Pharmacy, Vrije Universiteit, Brussels, Belgium) reproduced key NASH characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 hepatic stellate cells to multiple factors that play a role in the onset of NASH...
Read More

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES